Losartan Decreases Cardiac Muscle Fibrosis and Improves Cardiac Function in Dystrophin-Deficient Mdx Mice

Recent studies showed that chronic administration of losartan, an angiotensin II type I receptor antagonist, improved skeletal muscle function in dystrophin-deficient mdx mice. In this study, C57BL/10ScSn-Dmdmdx/J female mice were either untreated or treated with losartan (n = 15) in the drinking water at a dose of 600 mg/L over a 6-month period. Cardiac function was assessed via in vivo high frequency echocardiography and skeletal muscle function was assessed using grip strength testing, Digiscan monitoring, Rotarod timing, and in vitro force testing. Fibrosis was assessed using picrosirius red staining and Image J analysis. Gene expression was evaluated using real-time polymerized chain reaction (RT-PCR). Percentage shortening fraction was significantly decreased in untreated (26.9% ± 3.5%) mice compared to losartan-treated (32.2% ± 4.2%; P < .01) mice. Systolic blood pressure was significantly reduced in losartan-treated mice (56 ± 6 vs 69 ± 7 mm Hg; P < .0005). Percentage cardiac fibrosis was significantly reduced in losartan-treated hearts (P < .05) along with diaphragm (P < .01), extensor digitorum longus (P < .05), and gastrocnemius (P < .05) muscles compared to untreated mdx mice. There were no significant differences in skeletal muscle function between treated and untreated groups. Chronic treatment with losartan decreases cardiac and skeletal muscle fibrosis and improves cardiac systolic function in dystrophin-deficient mdx mice.

[1]  Eric P. Hoffman,et al.  Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.

[2]  G. MacGowan,et al.  Contrasting effects of steroids and angiotensin‐converting‐enzyme inhibitors in a mouse model of dystrophin‐deficient cardiomyopathy , 2009, European journal of heart failure.

[3]  R. Sheppard,et al.  Fibrosis in heart disease: understanding the role of transforming growth factor‐β1 in cardiomyopathy, valvular disease and arrhythmia , 2006, Immunology.

[4]  J. Faulkner,et al.  Contractile properties of skeletal muscles from young, adult and aged mice. , 1988, The Journal of physiology.

[5]  W. Colucci,et al.  Regulation of angiotensin II‐stimulated osteopontin expression in cardiac microvascular endothelial cells: Role of p42/44 mitogen‐activated protein kinase and reactive oxygen species * , 2001, Journal of cellular physiology.

[6]  N. Raben,et al.  Modulation of disease severity in mice with targeted disruption of the acid α-glucosidase gene , 2000, Neuromuscular Disorders.

[7]  R. Wada,et al.  Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[8]  E. Hoffman,et al.  Dystrophin-deficient cardiomyopathy in mouse: Expression of Nox4 and Lox are associated with fibrosis and altered functional parameters in the heart , 2008, Neuromuscular Disorders.

[9]  Marc K. Halushka,et al.  Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome , 2006, Science.

[10]  W. Liu,et al.  Journal of Cardiovascular Magnetic Resonance Open Access Early Manifestation of Alteration in Cardiac Function in Dystrophin Deficient Mdx Mouse Using 3d Cmr Tagging , 2009 .

[11]  J. Belmont,et al.  Genetic Predictors and Remodeling of Dilated Cardiomyopathy in Muscular Dystrophy , 2005, Circulation.

[12]  C. Padovani,et al.  [Blockade of renin-angiotensin system attenuates cardiac remodeling in rats undergoing aortic stenosis]. , 2005, Arquivos brasileiros de cardiologia.

[13]  T. Suzuki,et al.  Chronic effect of losartan in a murine model of dilated cardiomyopathy: comparison with captopril. , 1995, The Journal of pharmacology and experimental therapeutics.

[14]  E. Hoffman,et al.  Evaluation of Skeletal and Cardiac Muscle Function after Chronic Administration of Thymosin β-4 in the Dystrophin Deficient Mouse , 2010, PloS one.

[15]  A. Saxena,et al.  Duchenne Muscular Dystrophy: Prevalence and patterns of cardiac involvement , 2005, Indian journal of pediatrics.

[16]  J. Chamberlain,et al.  Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  Vincenzo Giglio,et al.  Left ventricular function and response to enalapril in patients with Duchenne muscular dystrophy during the second decade of life. , 2007, The American journal of cardiology.

[18]  A. Toutain,et al.  Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up. , 2007, American heart journal.

[19]  G. S. Pandey,et al.  Preclinical drug trials in the mdx mouse: Assessment of reliable and sensitive outcome measures , 2009, Muscle & nerve.

[20]  Zhonglin Xie,et al.  ERK1/2 and JNKs, but not p38 kinase, are involved in reactive oxygen species‐mediated induction of osteopontin gene expression by angiotensin II and interleukin‐1β in adult rat cardiac fibroblasts , 2004, Journal of cellular physiology.

[21]  A. Nakamura,et al.  Progression of dystrophic features and activation of mitogen‐activated protein kinases and calcineurin by physical exercise, in hearts of mdx mice , 2002, FEBS letters.

[22]  H. Bécane,et al.  Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. , 2005, Journal of the American College of Cardiology.

[23]  Leonardo A. M. Zornoff,et al.  O bloqueio do sistema renina-angiotensina atenua a remodelação cardíaca de ratos submetidos a estenose aórtica , 2005 .

[24]  B. Wong,et al.  Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings , 2004, Neuromuscular Disorders.

[25]  M. Marques,et al.  Long‐term therapy with deflazacort decreases myocardial fibrosis in mdx mice , 2009, Muscle & nerve.

[26]  Zhidong Wang,et al.  Angiotensin II Induces Inflammatory Response Partly Via Toll-Like Receptor 4-Dependent Signaling Pathway in Vascular Smooth Muscle Cells , 2009, Cellular Physiology and Biochemistry.

[27]  J. Lecron,et al.  Role of interleukin‐6 in cardiomyocyte/cardiac fibroblast interactions during myocyte hypertrophy and fibroblast proliferation , 2005, Journal of cellular physiology.

[28]  M. Entman,et al.  Angiotensin II Blockade Reverses Myocardial Fibrosis in a Transgenic Mouse Model of Human Hypertrophic Cardiomyopathy , 2001, Circulation.

[29]  D. Judge,et al.  Angiotensin II type 1 receptor blockade attenuates TGF-β–induced failure of muscle regeneration in multiple myopathic states , 2007, Nature Medicine.

[30]  T. Iwasaka,et al.  N-acetylcysteine abolishes the protective effect of losartan against left ventricular remodeling in cardiomyopathy hamster. , 2008, Antioxidants & redox signaling.

[31]  M. Horiuchi,et al.  AT2 receptor mediates the cardioprotective effects of AT1 receptor antagonist in post-myocardial infarction remodeling. , 2006, Life sciences.

[32]  Ying E Zhang,et al.  Non-Smad pathways in TGF-β signaling , 2009, Cell Research.